SRTA
Strata Critical Medical, Inc.5.32
+0.23+4.52%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Reaffirms momentum, flags reg delays.
Q&A largely reaffirmed the prepared remarks' strong momentum and raised guidance, but added nuance on regulatory delays: continuous distribution for hearts and livers deprioritized amid pressing issues, with no firm timeline despite being the end goal. Management touted cross-sell traction, with 40% of sequential logistics growth from clinical customers embracing integrated services that save costs. Smaller competitors are proactively approaching for M&A, spooked by rising standards Strata already meets. Early-year shorter trips and Northeast weather? Normal ebb and flow. Radiopharma stays a low-key pilot, not acquisition bait. Confident tone holds; watch cross-sell scale and deal closes.
Key Stats
Market Cap
459.47MP/E (TTM)
-Basic EPS (TTM)
-0.42Dividend Yield
0%Recent Filings
8-K
Q4 revenue up 83.5%
Strata Critical Medical crushed Q4 2025 with revenue surging 83.5% to $66.8 million, fueled by 35.3% organic Logistics growth and Keystone's Clinical ramp-up. Full-year Adjusted EBITDA hit $14.1 million, topping guidance. They raised 2026 outlook to $260-275 million revenue, $29-33 million Adjusted EBITDA. Cash burn hit due to one-time hits.
10-K
FY2025 results
Strata Critical Medical posted FY2025 revenue of $197M, up 34% y/y, with Logistics driving $177M (20% growth from flight hours and new contracts) while the new Clinical segment added $20M post-Keystone acquisition in September. Gross margin expanded to 21% from 20%, reflecting leverage in ground services and Clinical's higher margins, though operating loss widened to $(22M) on $61M SG&A (up 20%, including $4.7M Drulias settlement and M&A costs). Adjusted EBITDA swung to $14M (7% margin) from $4M. Q4 momentum accelerated with Keystone integration; liquidity stood at $61M. Yet organ donor supply flattened recently.
8-K
Strata closes $30M ABL facility
Strata Critical Medical closed a $30M asset-based revolving credit facility with JPMorgan Chase on January 30, 2026, expandable to $50M, maturing January 30, 2029. SOFR + 2% interest funds working capital needs; secured by personal property liens but excludes owned aircraft. Springing 1.05x fixed charge covenant triggers below $5M availability.
8-K
Appoints healthcare CEO to board
Strata Critical Medical expanded its board from eight to nine directors, appointing William L. Cook III as Class I director effective December 2, 2025. The independent director, CEO of Vail Health with deep transplant and healthcare leadership, joins the Compensation and Nominating Committees. Granted 33,157 RSUs vesting at the 2027 annual meeting. His expertise bolsters scaling efforts.
8-K
Q3 revenue jumps 37%
Strata Critical Medical reported Q3 revenue up 36.7% to $49.3M, with organic growth of 29.0% excluding Keystone, while net loss widened to $(9.7)M from investment losses and legal reserves. Medical Segment Adjusted EBITDA surged 93.5% to $7.6M (15.3% margin), boosted by Air Logistics and Organ Placement. Raised 2025 revenue guidance to $185-195M. Keystone integration advances swiftly.
IPO
Employees
Sector
Industry
FLYYQ
Spirit Aviation Holdings, Inc.
0.20+0.00
FTAI
FTAI Aviation Ltd.
168.63-2.06
HRBR
Harbor Diversified, Inc.
0.85+0.12
JETR
Star Jets International, Inc.
0.01+0.00
JOBY
Joby Aviation, Inc.
14.07-0.12
SKAS
Saker Aviation Services Inc.
6.80+0.00
SOAR
Volato Group, Inc.
1.05-0.05
SRFM
Surf Air Mobility Inc.
1.94+0.00
SSKN
Strata Skin Sciences, Inc.
1.33-0.03
UP
Wheels Up Experience Inc.
0.69+0.02